Understanding CPA5: Potential Drug Target and Biomarker (G93979)

Target Name: CPA5

NCBI ID: G93979

CPA5

Understanding CPA5: Potential Drug Target and Biomarker

CPA5, also known as Carboxypeptidase A5 (isoform 1), is a protein that is expressed in various tissues throughout the body. It is a member of the superfamily of proteins known as carboxypeptidases and is involved in the breakdown of peptides. This protein has been identified as a potential drug target and may also be used as a biomarker for certain diseases.

CPA5 is a 23-kDa protein that is expressed in a variety of tissues, including muscle, heart, brain, and pancreas. It is primarily localized to the cytoplasm of cells and is found in high concentrations in the nuclei. CPA5 has a molecular weight of 66 kDa and a calculated pI of 6.5.

CPA5 is involved in the breakdown of peptides and has been shown to be involved in a number of physiological processes in the body. For example, it has been shown to be involved in the regulation of muscle growth and development, as well as in the development and maintenance of the blood-brain barrier. CPA5 has also been shown to be involved in the regulation of inflammation and immune responses.

CPA5 has also been identified as a potential drug target. Its involvement in the breakdown of peptides makes it a potential target for small molecules that can inhibit its activity. This has led to the development of a number of compounds that have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, CPA5 has also been identified as a potential biomarker for certain diseases. Its involvement in the breakdown of peptides makes it a potential indicator of protein homeostasis, which is the balance between the concentration of protein in the body and the rate of protein synthesis. This suggests that changes in the level of CPA5 may be an indication of certain diseases, such as cancer or neurodegenerative disorders.

CPA5 is also known as Isoform 1 (ISO 1) and it is a member of the Carboxypeptidase family 1. This family also includes other proteins that are involved in the breakdown of peptides, including Isoform 2 (ISO 2) and Isoform 3 (ISO 3 ).

In conclusion, CPA5 is a protein that is expressed in various tissues throughout the body and is involved in the breakdown of peptides. Its potential as a drug target and biomarker make it an attractive target for research and development of new treatments for a variety of diseases . Further studies are needed to fully understand its role in the body and its potential as a drug and biomarker.

Protein Name: Carboxypeptidase A5

The "CPA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets